Abstract: Agents useful for modulating the dioxin/aryl hydrocarbon receptor (AhR) can now be identified by determining the binding to said receptor and whether said agent suppresses or inhibits the expression of a gene substantially consisting of a sequence according to one of SEQ. ID. NO. 1 and SEQ. ID. NO. 2; a nucleotide sequence functionally homologous, or substantially homologous, or at least 90% identical to one of SEQ. ID. NO. 1 and SEQ. ID. NO. 2; and a nucleotide sequence complementary to the nucleotide sequence of SEQ. ID. NO. 1 or SEQ. ID. NO. 2. Such agents find utility in pharmaceutical compositions and methods for the prevention, alleviation or treatment of diseases involving gastrointestinal hyperplasia, such as gastrointestinal cancer or gastric cancer.

Abstract: A pharmaceutical composition comprises the sequence of SEQ ID NO:s 3-5 or pharmaceutically equivalent sequences. Methods employing the pharmaceutical compositions include treatments to increase angiogenesis, to stimulate HIF-1? function, to treat hypoxia-related conditions, and to maintain normal cell functions under hypoxia.

Abstract: A mammalian polypeptide designated Inhibitory PAS Domain Protein (IPAS) is useful for the inhibition of angiogenesis and/or tumor progression. Screening methods exist to identify compounds potentially useful as medicaments for the treatment of medical conditions related to angiogenesis or tumor progression.

Abstract: The present invention relates a mammalian polypeptide designated Inhibitory PAS Domain Protein (IPAS) which polypeptide is useful for the inhibition of angiogenesis and/or tumor progression. The invention also relates to screening methods for compounds potentially useful as medicaments for the treatment of medical conditions related to angiogenesis or tumor progression.

Abstract: Agents useful for modulating the dioxin/aryl hydrocarbon receptor (AhR) can now be identified by determining the binding to said receptor and whether said agent suppresses or inhibits the expression of a gene substantially consisting of a sequence according to one of SEQ.ID. NO. 1 and SEQ.ID. NO. 2; a nucleotide sequence functionally homologous, or substantially homologous, or at least 90% identical to one of SEQ.ID. NO. 1 and SEQ.ID. NO. 2; and a nucleotide sequence complementary to the nucleotide sequence of SEQ.ID. NO. 1 or SEQ.ID. NO. 2. Such agents find utility in pharmaceutical compositions and methods for the prevention, alleviation or treatment of diseases involving gastrointestinal hyperplasia, such as gastrointestinal cancer or gastric cancer.

Abstract: The present invention makes available powerful tools for the study of cancer, based on a novel expression construct for a constitutively active hydrocarbon receptor CA-AhR. The invention further comprises transgenic non-human animals, preferably mammals, expressing CA-AhR in one or more tissues thereof. An animal model based on the transgenic non-human animals forms the basis for novel methods e.g. for the study of cancer; for the screening of compounds, such as drug candidates; for the investigation of the molecular mechanisms of cancer, in particular stomach cancer; for the investigation of the mechanisms of highly differentiated adenocarcinoma etc. Likewise, in vitro models based on transformed cells or cell lines, functionally incorporating the inventive construct are disclosed.

Abstract: A mammalian polypeptide designated Inhibitory PAS Domain Protein (IPAS) is useful for the inhibition of angiogenesis and/or tumor progression. Screening methods exist to identify compounds potentially useful as medicaments for the treatment of medical conditions related to angiogenesis or tumor progression.

Abstract: A pharmaceutical composition comprises the sequence of SEQ ID NO:s 3-5 or pharmaceutically equivalent sequences. Methods employing the pharmaceutical compositions include treatments to increase angiogenesis, to stimulate HIF-1? function, to treat hypoxia-related conditions, and to maintain normal cell functions under hypoxia.

Abstract: The present invention makes available powerful tools for the study of cancer, based on a novel expression construct for a constitutively active hydrocarbon receptor CA-AhR. The invention further comprises transgenic non-human animals, preferably mammals, expressing CA-AhR in one or more tissues thereof. An animal model based on the transgenic non-human animals forms the basis for novel methods e.g. for the study of cancer; for the screening of compounds, such as drug candidates; for the investigation of the molecular mechanisms of cancer, in particular stomach cancer; for the investigation of the mechanisms of highly differentiated adenocarcinoma etc. Likewise, in vitro models based on transformed cells or cell lines, functionally incorporating the inventive construct are disclosed.

Abstract: The present invention relates a mammalian polypeptide designated Inhibitory PAS Domain Protein (IPAS) which polypeptide is useful for the inhibition of angiogenesis and/or tumor progression. The invention also relates to screening methods for compounds potentially useful as medicaments for the treatment of medical conditions related to angiogenesis or tumor progression.

Abstract: The present invention relates to a method for identifying compounds capable of modulating the function of a functional domain of human HIF-1&agr;, said method comprising (i) contacting a candidate compound with a variant of human HIF-1&agr;, said variant essentially lacking at least one functional domain of human HIF-1&agr;, or having a mutation making at least one functional domain of human HIF-1&agr; essentially inactive, said functional domain or domains being selected from the group consisting of (a) the PAS-B domain located in human HIF-1&agr; between amino acids 178 and 390, (b) the C-terminal nuclear localization sequence (NLS) located in human HIF-1&agr; essentially at amino acids 718 to 721, and (c) the transactivator/coactivator domain (N-TAD) located in human HIF-1&agr; essentially between amino acids 531 to 584, and (d) the transactivator/coactivator domain (C-TAD) located in human HIF-1&agr; essentially between amino acids 813 and 826, and (ii) determining the effect of the candidate compou

Abstract: Alterations to the transactivation (N-TAD) domain of HIF-1 alpha demonstrate this domain contains structures necessary for hypoxia-inducible transactivation, oxygen-dependent degradation, and VHL-HIF-1 alpha interaction. HIF-1 alpha sequences with alterations of the N-TAD domain, fragments and analogs thereof are useful in modifying or regulating the activity of bioentities. Agonists and antagonists of the N-TAD domain of HIF-1 alpha are also useful in modifying or regulating the activity of bioentities.